International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 07 July 2023

Page No: 1373-1377

DOI: https://doi.org/10.47191/ijmscrs/v3-i7-26, Impact Factor: 6.597

Dermatomyositis: A Comprehensive Review of a Complex Autoimmune Disease

Monserrat Espinosa Ramos[1], Marisol Deleón Rodríguez[1], Alma Yaneli Alvarez Romero[2], Lorena Estefani Alfaro García[3], María Erika Boza Medrano[4], Susana González Hernández[5], Manuel Alejandro Coello Manuell[6]

[1]Hospital Chiapas Nos Une Dr. Jesús Gilberto Gómez Maza, Tuxtla Gútierrez, Chiapas, México.

[2]Hospital General Regional 1 Tijuana Instituto Mexicano del Seguro Social, México.

[3]Hospital General de Zona #2 Dr. Efrén Correa Magallanes. Fresnillo, Zacatecas, México.

[4]Hospital general de zona #1 Instituto Mexicano del Seguro Social. Durango. Durango, México.

[5]Hospital General Dr. Dario Fernandez Fierro. Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Ciudad de México, México.

[6]Facultad de Medicina, Universidad Nacional Autónoma de México. México.

ABSTRACT

Dermatomyositis is a rare and complex systemic autoimmune disease that primarily affects the musculoskeletal and cutaneous systems. In this review article, the clinical, pathophysiologic, diagnostic, and therapeutic aspects of dermatomyositis are examined in detail. The characteristic clinical presentation of the disease, which includes symmetrical and proximal muscle weakness, as well as distinctive cutaneous eruptions, such as erythema heliotrope and Gottron papules, is discussed. The underlying mechanisms of the pathophysiology of dermatomyositis, involving a dysregulated immune response, chronic inflammation, and tissue damage to muscles and skin, are discussed.

Diagnostic approaches are detailed, involving the integration of clinical findings, dermatological findings, laboratory tests and, in some cases, imaging studies and tissue biopsy. In addition, the therapeutic strategies used are presented, including the use of immunosuppressive drugs, physical and occupational therapy, and supportive measures. The importance of a multidisciplinary approach and individualized management to optimize symptom control and improve the quality of life of patients with dermatomyositis is emphasized. This review aims to provide a comprehensive and up-to-date overview of this complex disease, with the hope of fostering a better understanding, diagnosis, and treatment of dermatomyositis.

ARTICLE DETAILS

Published On:
21 July 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Dermatomyositis is a chronic systemic autoimmune disease characterized by simultaneous inflammation of the muscles and skin, in which the individual's immune system mistakenly attacks its own cells and tissues. This rare condition predominantly affects proximal muscle groups and manifests clinically with progressive muscle weakness and characteristic skin rashes.1

At the pathophysiological level, dermatomyositis is attributed to inappropriate activation of the immune system, specifically the lymphocyte response, which triggers excessive production of inflammatory cytokines and infiltration of inflammatory cells into the affected tissues. This abnormal immune response may be related to genetic predispositions and environmental factors, although the exact etiology has not yet been fully elucidated.1

PATHOPHYSIOLOGY

The pathophysiology of dermatomyositis is a complex process involving a dysregulated immune response, chronic inflammation and tissue damage in the muscles and skin. This autoimmune disease is characterized by inappropriate activation of the immune system, specifically the T-lymphocyte response, which triggers a series of pathological events.2

Genetic and environmental factors are believed to contribute to the development of dermatomyositis. Studies suggest the involvement of genetic variants in genes related to the immune system and regulation of the inflammatory response. In addition, environmental factors such as viral infections, exposure to ultraviolet radiation, certain drugs and other triggering stimuli may play a role in immune dysregulation.2

In dermatomyositis, T lymphocytes infiltrate muscle and skin tissues, triggering a local immune response. An accumulation of inflammatory cells, including lymphocytes, plasma cells and macrophages, has been observed in the affected tissues. These cells produce and release inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6), which contribute to inflammation and tissue damage.3

The formation of immune complexes also plays a role in the pathophysiology of dermatomyositis. The presence of immune complexes deposited in blood vessels and at the junction between the epidermis and dermis in affected skin has been observed. These immune complexes can activate the complement system and attract additional inflammatory cells, exacerbating the local inflammatory response.4

The resulting chronic inflammation in the muscles and skin leads to tissue damage. In muscles, inflammation causes destruction of muscle cells, resulting in weakness and decreased muscle function. In addition, inflammation can affect the small blood vessels that supply the muscles, leading to ischemia and further tissue injury.4

In the skin, chronic inflammation causes characteristic changes, such as perivascular inflammation and infiltration of inflammatory cells into the dermis. These histological changes are reflected in the clinical manifestations of dermatomyositis, such as erythema heliotrope and erythematous or violaceous papules on the finger joints.4

Although the exact mechanisms that trigger the pathophysiology of dermatomyositis are not yet fully understood, it is postulated that there is a complex interaction between genetic, immunologic and environmental components. These factors converge to elicit an abnormal immune response and subsequent chronic inflammation and tissue damage in the muscles and skin.4

The pathophysiology of dermatomyositis involves a dysregulated immune response, inflammatory cell infiltration, inflammatory cytokine release, immune complex formation, and tissue damage to muscles and skin. Understanding these pathological processes is critical to the development of targeted and more effective therapeutic approaches for this complex autoimmune disease.4

EPIDEMIOLOGY

Dermatomyositis is a rare systemic autoimmune disease that primarily affects the pediatric and young adult population, although it can also occur in older individuals. The incidence and prevalence of this condition vary in different geographic regions and ethnic groups.5

In general, the incidence of dermatomyositis is estimated to be approximately 1 to 10 cases per million people per year. However, the incidence may be slightly higher in certain populations, such as children, where it is estimated to be approximately 3 to 4 cases per million children per year. In addition, dermatomyositis appears to have a higher incidence in females than in males, with a ratio of approximately 2:1.5.

In terms of prevalence, dermatomyositis is estimated to affect about 5 to 10 persons per 100,000 population in the general population. Again, a higher prevalence is observed in the pediatric population, with a prevalence of approximately 3 to 4 cases per 100,000 children. The disease tends to be more common in people of Caucasian descent, although it can also occur in individuals of other ethnicities.6

Dermatomyositis can occur at any age, but there is a bimodal distribution in terms of onset. In childhood, the most common age of onset is between 5 and 10 years, while in adulthood, the peak of onset occurs between 40 and 60 years of age. However, cases of dermatomyositis have been reported in infants and older adults.7

In relation to risk factors, an association between dermatomyositis and certain family history has been observed, suggesting a genetic predisposition. Genes related to immune response and regulation of inflammation have been identified as possible genetic susceptibilities for the development of the disease. In addition, a triggering role of environmental factors, such as viral infections and exposure to ultraviolet radiation, has been suggested.8

Dermatomyositis is a rare systemic autoimmune disease that predominantly affects the pediatric and young adult population. Although the incidence and prevalence of the disease are low overall, there are variations by age, gender, ethnicity, and geographic region. Understanding the epidemiology of dermatomyositis is critical to the early identification, accurate diagnosis and appropriate management of this complex autoimmune condition.8

CLINIC

Dermatomyositis is a systemic autoimmune disease characterized by a wide range of clinical manifestations primarily affecting the musculoskeletal and cutaneous systems. These distinctive clinical symptoms allow the diagnosis and differentiation of this condition from other similar diseases.9

At the musculoskeletal level, dermatomyositis manifests predominantly with symmetrical and proximal muscle weakness, meaning that muscles close to the joints, such as those of the neck, shoulders, arms and hips, are most affected. This muscle weakness may initially manifest as difficulty performing everyday activities that require strength, such as lifting heavy objects, climbing stairs, combing one's hair or getting up from a chair. As the disease progresses, the weakness may affect other muscle groups and lead to a significant decrease in mobility and functional ability.9

As for cutaneous manifestations, dermatomyositis is characterized by the presence of characteristic skin eruptions. The most recognized sign is erythema heliotrope, which manifests as a violaceous reddening of the upper eyelids and may extend to photoexposed areas such as the face, neck, chest and dorsum of the hands. In addition, erythematous or violaceous papules may be seen on the finger joints, known as Gottron's sign. Other cutaneous findings may include

periorbital edema, telangiectasias, skin ulcers and nail changes such as longitudinal splitting, thickening or thinning.9

In addition to musculoskeletal and cutaneous symptoms, dermatomyositis may also present with additional systemic manifestations affecting other organs and body systems. These may include joint inflammation (arthritis), respiratory problems such as cough, shortness of breath or interstitial pneumonia, cardiac complications such as myocarditis or arrhythmias, gastrointestinal disorders such as dysphagia or inflammation of the gastrointestinal tract, connective tissue disorders such as Raynaud's phenomenon, and nervous system involvement that may manifest as facial weakness, dysphagia or alterations in sensation.9

It is important to note that the clinical presentation of dermatomyositis can vary significantly among individuals, making diagnosis difficult. Some patients may experience more pronounced muscular symptoms, while others may present predominantly with cutaneous manifestations. In addition, the severity of symptoms can range from mild and self-limiting to more severe and progressive forms of the disease.10

In summary, dermatomyositis is characterized by the presence of symmetric and proximal muscle weakness, as well as characteristic skin eruptions such as erythema heliotrope and Gottron's papules. In addition, there may be additional systemic manifestations affecting different body systems. Proper identification and evaluation of these clinical findings are critical to establish an accurate diagnosis and for the comprehensive management of dermatomyositis.11

DIAGNOSIS

Diagnosis of dermatomyositis involves a comprehensive evaluation that combines clinical information, dermatologic findings, laboratory test results and, in some cases, imaging studies and tissue biopsy. Early and accurate identification of the disease is crucial to initiate appropriate treatment and avoid potential complications.12

Clinical evaluation plays a key role in the diagnosis of dermatomyositis. The physician will collect detailed information on presenting symptoms such as muscle weakness, skin rashes, joint pain or other systemic symptoms. In addition, a relevant medical and family history will be investigated, as well as any exposure to known triggers. The clinical evaluation will also include a thorough physical examination to identify characteristic findings, such as erythema heliotrope, Gottron's papules and other cutaneous signs.13

Laboratory tests play an important role in the diagnosis of dermatomyositis. Blood tests may be performed to evaluate the levels of muscle enzymes, such as creatine kinase (CK), aldolase and lactate dehydrogenase (LDH), which are often elevated in patients with dermatomyositis due to muscle damage. In addition, specific antibodies associated with the disease, such as antinuclear antibodies (ANA), anti-Mi-2 antibodies and anti-Jo-1 antibodies, will be sought. The presence of these autoantibodies may support the diagnosis of dermatomyositis.13

Imaging, such as magnetic resonance imaging (MRI) and electromyography (EMG), can be used as complementary tools in the diagnosis of dermatomyositis. MRI can reveal inflammation and edema in the affected muscles, while EMG can help assess the function and electrical activity of the muscles. These studies can provide objective evidence of muscle inflammation and support the diagnosis of dermatomyositis.14

In some cases, a muscle biopsy may be performed to confirm the diagnosis of dermatomyositis. During this procedure, a sample of muscle tissue is obtained through a small incision and analyzed under a microscope. The muscle biopsy may reveal findings characteristic of the disease, such as the presence of inflammatory infiltrates, muscle necrosis and degenerative changes. These histological findings, together with clinical and laboratory data, support the diagnosis of dermatomyositis.15

The diagnosis of dermatomyositis is based on a comprehensive evaluation involving clinical information, dermatological findings, laboratory tests, imaging studies and, in some cases, muscle biopsy. The combination of these approaches makes it possible to establish an accurate diagnosis and differentiate dermatomyositis from other similar diseases. An early and accurate diagnosis is essential to initiate appropriate treatment and improve the prognosis of patients with dermatomyositis.16

TREATMENT

The treatment of dermatomyositis is based on a multidisciplinary approach combining pharmacological measures, physical and occupational therapy, and supportive measures. The main goal of treatment is to control inflammation, reduce symptoms and improve patients' quality of life. The management of dermatomyositis is usually individualized and tailored to the specific needs of each patient.17

The mainstay of pharmacological treatment of dermatomyositis is the use of immunosuppressive drugs. Corticosteroids, such as prednisone, are considered the first-line therapy and are used to reduce inflammation and suppress the abnormal immune response. However, because of the potential long-term side effects of corticosteroids, one seeks to gradually reduce their dosage as the disease is controlled.17

In more severe or resistant cases to corticosteroid therapy, other immunosuppressants such as methotrexate, azathioprine or mycophenolate mofetil may be used. These drugs help to further suppress the immune response and may reduce the need for high-dose corticosteroids. However, their use requires careful supervision due to possible side effects and the need for regular monitoring of liver and blood function.17

In addition to immunosuppressants, other drugs such as hydroxychloroquine, which has anti-inflammatory properties and may help improve the cutaneous symptoms of dermatomyositis, may be considered in some cases. Tumor necrosis factor-alpha (TNF-α) inhibitors, such as infliximab or etanercept, may also be used in select cases of refractory dermatomyositis.17

Physical and occupational therapy is an integral part of the treatment of dermatomyositis. These therapeutic approaches help to improve patients' muscle strength, mobility and functional ability. Supervised and individually tailored exercise programs can be beneficial in strengthening weakened muscles and maintaining joint function. Occupational therapy focuses on improving the ability to perform daily activities and adapt to physical limitations.18

In addition, supportive measures are essential for the management of dermatomyositis. This may include protection of the skin from excessive sun exposure through the use of sunscreens and protective clothing. In cases of swallowing difficulty (dysphagia), dietary modifications and swallowing therapy may be recommended to prevent dietary complications. In addition, mobility aids such as assistive devices and environmental adaptations can be provided to improve the patient's autonomy.18

It is important to note that the treatment of dermatomyositis is individualized and requires regular evaluation and follow-up by a specialized medical team. The choice of medications and therapies is based on the severity of symptoms, response to treatment and possible side effects. The main goal is to keep the disease under control and improve patients' long-term quality of life.18

CONCLUSION

In conclusion, dermatomyositis is a complex systemic autoimmune disease that mainly affects the musculoskeletal and cutaneous systems. It is characterized by chronic inflammation of the muscles and the presence of characteristic skin rashes. This rare disease can have a significant impact on patients' quality of life, as it is associated with progressive muscle weakness, functional limitations and distinctive skin manifestations.

Dermatomyositis has a wide variability in its clinical presentation, which often makes it difficult to diagnose. Physicians should carefully consider muscle symptoms, dermatologic findings, and laboratory test results to establish an accurate diagnosis and differentiate dermatomyositis from other similar diseases.

The management of dermatomyositis requires a multidisciplinary approach combining pharmacological measures, physical and occupational therapy, and supportive measures. The use of immunosuppressive drugs, such as corticosteroids and other immunosuppressants, is essential to control inflammation and reduce symptoms. Physical and occupational therapy plays an important role in muscle strengthening, improving mobility and adapting to physical limitations. In addition, supportive measures, such as sun protection and dietary modifications, help mitigate the effects of the disease and improve patients' quality of life.

Although dermatomyositis can have a chronic and recurrent course, early diagnosis and appropriate treatment can help control symptoms and prevent long-term complications. However, it is important to note that the disease is heterogeneous in its presentation and prognosis, underscoring the importance of regular evaluation and follow-up by a specialized medical team.

In general, the comprehensive approach to dermatomyositis requires an individualized approach, taking into account the characteristics and needs of each patient. Continued research into the pathophysiology and management of the disease is essential to improve the understanding and treatment of dermatomyositis, with the ultimate goal of improving the quality of life of patients affected by this complex autoimmune disease.

REFERENCES

I. Dalakas M.C. Polymyosits, dermatomyositis and inclusion-body myositis. N Engl J Med, 325 (1991), pp.1487-1498 http://dx.doi.org/10.1056/NEJM199111213252106

II. Miller F.W.. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am, 20 (1994), pp. 811-826.

III. Bohan A, Peter J.B.. Polymyositis and dermatomyositis: Parts 1 and 2. N Engl J Med, 292 (1975),pp.344-347 http://dx.doi.org/10.1056/NEJM197502132920706

IV. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore), 70 (1991), pp. 360-374.

V. Mimori T, Imura Y, Nakashima R, Yoshifugi H.. Autoantibodies in idiopathic inflammatory myopathy: An update on clinical and pathophysiological significance. Curr Opin Rheumatol, 19 (2007), pp. 523-529 http://dx.doi.org/10.1097/BOR.0b013e3282f01a8c.

VI. Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity, 39 (2006), pp. 233-241 http://dx.doi.org/10.1080/08916930600622884

VII. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum, 28 (1985), pp. 796-803.

VIII. Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E.. The major dermatomyositis-specific

Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum, 38 (1995), pp. 1389-1399.

IX. Ge Q, Nilasena DS, O'Brien CA, Frank MB, Targoff I.N. Molecular analysis of a major antigenic region of the 240-kD protein of Mi- autoantigen. J Clin Invest, 96 (1995), pp. 1730-1737 http://dx.doi.org/10.1172/JCI118218

X. Seelig HP, Renz M, Targoff IN, Ge Q, Frank M.B.Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum, 39 (1996), pp. 1769-1771.

XI. Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis, 65 (2006), pp. 242-245 http://dx.doi.org/10.1136/ard.2005.040717

XII. Targoff IN, Johnson AE, Miller F.W. Antibody to signal recognition particle in polymyositis. Arthritis Rheum, 33 (1990), pp. 1361-1370.

XIII. Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum, 35 (1992), pp. 449-456.

XIV. Hengstman GJ, Ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis, 65 (2006), pp. 1635-1638. http://dx.doi.org/10.1136/ard.2006.052191

XV. Arlet JB, Dimitri D, Pagnoux C, Boyer O, Maisonobe T, Authier FJ, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord, 16 (2006), pp. 334-336. http://dx.doi.org/10.1016/j.nmd.2006.03.002

XVI. Euwer RL, Sontheimer R.D. Dermatologic aspects of myositis. Curr Opin Rheumatol, 6 (1994), p. 583-589.

XVII. Sontheimer R.D.Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol, 11 (1999), pp. 475-482.

XVIII. Kovacs SO, Kovacs S.C. Dermatomyositis. J Am Acad Dermatol, 39 (1998), pp. 899-920.